Bristol-Myers Squibb Shareholder Alert – Kehoe Law Firm, P.C. Reminds Investors of Upcoming Lead Plaintiff Deadline

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

INVESTORS WHO BOUGHT BRISTOL-MYERS SQUIBB STOCK BETWEEN JANUARY 27, 2015 AND OCTOBER 9, 2016 HAVE UNTIL APRIL 10, 2018 TO SEEK APPOINTMENT AS LEAD PLAINTIFF.

PHILADELPHIA, PA, UNITED STATES, March 30, 2018 /EINPresswire.com/ — Kehoe Law Firm, P.C. is investigating claims on behalf of investors of Bristol-Myers Squibb to determine whether Bristol-Myers and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.

KEHOE LAW FIRM, P.C. REMINDS INVESTORS WHO BOUGHT BRISTOL-MYERS SQUIBB (NYSE: BMY) STOCK BETWEEN JANUARY 27, 2015 AND OCTOBER 9, 2016 THAT THEY HAVE UNTIL APRIL 10, 2018 TO SEEK APPOINTMENT AS LEAD PLAINTIFF.

On August 5, 2016, Bristol-Myers announced that its CheckMate-026 trial investigating the use of Opdivo (nivolumab) as monotherapy had failed, because it did not meet its primary endpoint of progression-free survival. On this news, Bristol-Myers's share price fell $12.04, or 16%, to close at $63.28 on August 5, 2016. Further, the stock price of Bristol-Myers continued to fall on the next trading day, declining another $2.98, or 4.7%, to close at $60.30 on August 8, 2016.

On October 9, 2016, Bristol-Myers disclosed the final primary analysis of CheckMate-026, including the finding that overall survival was only 14.4 months for Opdivo versus 13.2 months for chemotherapy. On this news, Bristol-Myers's share price fell $5.62, or 10.1%, to close at $49.81 on October 10, 2016.

On February 9, 2018, a class action lawsuit was filed against Bristol-Myers on behalf of investors who purchased Bristol-Myers securities between January 27, 2015 and October 9, 2016, both dates inclusive (the “Class Period”) seeking remedies under the Securities Exchange Act of 1934.

Allegedly, throughout the Class Period, BMY made materially false and/or misleading statements, as well as failed to disclose material adverse facts about BMY’s business, operations, and prospects. Specifically, BMY failed to disclose that BMY’s CheckMate-026 trial was more likely to fail than BMY represented; Bristol-Myers’ CheckMate-026 trial failed more severely than Bristol-Myers indicated it did in its August 5, 2016 announcements and disclosures; and, as a result, Bristol-Myers’ statements about its business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Bristol-Myers Squibb Shareholders and Investors: If you purchased Bristol-Myers stock between January 27, 2015 and October 9, 2016, inclusive, and have questions or concerns about your potential legal rights, please visit KLF's Bristol-Myers BMY page, contact John Kehoe, Esq., (215) 792-6676, Ext. 801, jkehoe@kehoelawfirm.com or e-mail info@kehoelawfirm.com.

John Kehoe, Esq.
Kehoe Law Firm, P.C.
2157926676, EXT. 801
email us here


Source: EIN Presswire

Tower Industries Launches New Anti-Ligature Shower Drain Covers

Anti-Ligature Shower Drain

The first Anti-Ligature drain for solid surface showers

Tower Industries Logo

Tower Industries

The first anti-ligature drain cover made exclusively for solid surface shower bases.

Tower not only met the need for a shower but met the need for a plumbing fixture as well.”

— Donna Dare Bickley

MASSILLON, OHIO, UNITED STATES, March 30, 2018 /EINPresswire.com/ — Tower Industries, America’s premier solid surface manufacturer, announced the launch of the first anti-ligature drain cover made exclusively for solid surface showers. When planning the construction of a bathroom for patients suffering from mental illness, it is essential in the design process to eliminate points where a cord, rope, or bed sheet can be looped or tied to a fixture to create a point of ligature, which may result in self-harm or in extreme cases, loss of life. Tower Industries’ patent-pending design accomplishes these goals and more.

“There were no drains [on the market] that were ligature resistant,” recalled Donna Dare Bickley, of JHS Architecture. “We only had drains that fit into solid surface sinks. [Tower] redesigned a better drain to fit into the shower. It’s a retrofit so it can just be plugged in and screwed in. It’s the first drain cover in the entire country. There’s not one anywhere else in the world. Tower not only met the need for a shower but met the need for a plumbing fixture as well.”

The drain can only be removed with a custom tool, so the maintenance team can easily access and clean the drain without giving the patients access to the drain space to hide contraband. Even though safety was the purpose of the design, function was kept as priority, as the drain can discharge five gallons per minute.

Visit https://TowerSurfaces.com/contact-us to learn more about Anti-Ligature Drains.

Devyn Bellamy
Tower Industries, Inc
3308372216
email us here


Source: EIN Presswire

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) Extended Trial Shows Patients Can Avoid Total Knee Replacement

AMPE has made it known that they are up for sale and if someone doesn’t buy or license the technology soon, they have the capability to proceed on their own.

Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

AMPE has made it known that they are up for sale and if someone doesn’t buy or license the technology soon, they have the capability to proceed on their own.”

— Ampio Pharmaceuticals (NASDAQ: AMPE)

MIAMI, FLORIDA, USA, March 30, 2018 /EINPresswire.com/ — (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)

View the complete article including the valuation gap and Investment summary with price target here: http://emerginggrowth.com/ampio-pharmaceuticals-inc-nasdaq-ampe-extended-trial-shows-patients-can-avoid-total-knee-replacement/

STRUT extended trial Results Show Reduction in TKR Surgeries
Possible First Line Therapy Designation
Likelihood of Approval Moves Forward
Big Pharma Opioid Manufacturers and OAK Drug Companies – Ideal Suitors
Risk Adjusted Earnings Model Supports Hefty $5 Billion + Valuation
Ampio Pharmaceuticals, Inc. (AMPE) announced extended clinical trial results from the STRUT study that showed use of AmpionTM lowered the rate of Total Knee Replacement (TKR) surgery by almost 50% over the use of Saline. Although this study was preliminary in nature it’s results were statistically relevant which means that when the study is completed there is a very high likelihood the outcome will be the same on the larger subset of people.

The impact of these results mean that AMPE can add to the list of current drug uses such as reducing pain, reducing inflammation, increasing function, and increasing global assessment. In addition, the company will be able to claim that the drug reduces TKR’s. This is a complete paradigm shift in the treatment of Osteoarthritis of the Knee (OAK) because now it’s viewed as a Disease Modifying Therapy (DMT). Top drug makers for OAK like Johnson and Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), Teva Pharmaceuticals (NYSE: TEVA), and Purdue focus on reducing pain in this patient population through the use of opiates. Another tier of drug companies which include names like Sanofi Adventis (NYSE: SNY) and Flexion (NASDAQ: FLXN) have focused corticosteroids and hyaluronic acid. AmpionTM is a biologic which means it’s synthesized from human proteins and has no addictive properties like opiates and can be used over and over again.

At the completion of this trial AMPE can include in their Biologics License Application (BLA) that use of AmpionTM will reduce the need for a TKR and up to 5 injections MUST be given before a TKR can be performed. The significance of this paradigm shift is that Orthopedic Surgeons will be required to give AmpionTM before a TKR is performed. The assumption that a large sales force will be needed to sell this drug is no longer valid for a DMT that becomes the new standard of care (SOC).

Trial Results

The STRUT study was a randomized, saline vehicle-controlled study to evaluate the safety and efficacy of AmpionTM when administered as three 4 ml inter articular (IA) injections delivered every two weeks. The study involved a total of 47 patients which was done in 2 phases. Phase 1 was a 7 patient single blind phase where all patients received AmpionTM. Phase 2 was randomized on a 1:1 basis with AmpionTM vs Saline. The primary endpoint was change in WOMAC pain between baseline and week 20. Using an IRB approved protocol AMPE followed up with 39 of 45 patients that completed the study 3.5 years later using a telephone questionnaire. The number of severe or KL-4 patients that would need a TKR was 16.

View the chart here: http://emerginggrowth.com/wp-content/uploads/2018/03/AMPE-Pic-1.png

What this chart shows is a statistically significant change in the number of TKR’s performed when using AmpionTM. Using the most conservative results AmpionTM can reduce the number of TKR surgeries by close to 50%. If you combine the two groups the numbers are even more impressive with a 29.4% likelihood of a TKR vs an 83.3% using saline. Keep in mind this data point is 3.5 years after injection. This is the most compelling data ever presented in OAK and KL-4 patients and represents a DMT that should be the new SOC and first-line therapy.

Effect on Orthopedic Landscape – First-Line Treatment Designation

Right now the orthopedic market does conservatively 640,000 TKR’s per year. AMPE is seeking a label for up to 5 injections of AmpionTM as needed. Orthopedic surgeons might have had the opportunity to make a judgement call on performing a TKR surgery instead of using AmpionTM. The release of this new this new data statistically shows that AmpionTM should be the first-line treatment in KL-4 patients before attempting a TKR. Ultimately the FDA makes the decisions on this matter but standard governmental guidelines reveals that any first-line treatment that shows an improvement of 30% over the existing standard of care would likely get the first-line treatment designation. Should AMPE get first-line treatment designation, orthopedic surgeons would be required to use AmpionTM before attempting a TKR. This labeling designation could give AMPE the TKR market on a silver platter.

When doctors see the effect of the drug on the most diseased patients, which is measured in weeks, it’s not hard to envision that use of the drug would be prescribed on less severe indications in place of prescribing opiates, corticosteroids and hyaluronic acid. Since doctors see patients at all stages of disease progression, this could be a real multiplier effect driving off label use of the drug.

OAK Drug Development Pipeline

There are 3 types of treatment options for KL-4 patients which include Hyaluronic Acid, Corticosteriods, and Opioids. All these existing treatment options depicted in the chart below fell short in clinical trials in reducing pain and increasing functional improvement but the story doesn’t end there. Two major reports written by the Journal of American Medical Association (JAMA) and the American Academy of Orthopedic Surgeons (AAOS) which both state they “do not support use of triamcinolone’”, “we cannot recommend using hyaluronic acid.” With the exception of AmpionTM, all these drugs in the chart below are FDA approved in this indication even though they missed their endpoint in clinical trials. It’s clear that two nationally recognized associations believe that none of these drugs work and a solution is needed. If approved, AmpionTM will be the only drug that actually met its endpoints.

View the chart here: http://emerginggrowth.com/wp-content/uploads/2018/03/AMPE-Picture-2.png

Major pharmaceuticals like Sanofi Adventis (NYSe: SNY), Johnson and Johnson (NYSE: JNJ), and Flexion (NASDAQ: FLXN) have failed to meet their endpoints in OAK but got marketing approval because there really aren’t any good options for patients until the advent of AMPE. None of these drugs work effectively long term and have proven to accelerate the disease progression. Injections do work for a short period but the mechanism of action is essentially taking a thin layer of cartilage and liquefying it to provide temporary relief. This isn’t a good long term solution. It is for this lack of a solution that state reimbursements are drying up for the top drug manufacturers. Another solution is needed and AMPE seems to have it.

View the data here: http://emerginggrowth.com/wp-content/uploads/2018/03/AMPE-3.png

AMPE – Excellent Buyout Candidate for Big Pharma

Current opiate pharmaceutical manufacturers like Johnson and Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), and Teva Pharmaceuticals (NYSE: TEVA) have come under major political scrutiny for their role in creating the opioid epidemic. Last month Trump announced $13 billion to combat the opioid crisis. Big opiate manufacturers like Johnson and Johnson (NYSE: JNJ) are likely to view the purchase of AMPE as not only good publicity but also has the upside of owning a platform technology. Many of these companies if not all were at the JP Morgan (NYSE: JPM) Conference in January and could be in the process of submitting bids to buy AMPE because it would fix the existing political situation and fill the hole left by the drop in sales they have experienced from the inability to market their drugs.

Investors might find that Merck (NYSE: MRK) is also an interesting suitor because it has not voiced plans to pursue its FORWARD trial which it completed in November 2017. MRK has made overtures that the Osteoarthritis Market needed disease modifying modalities that slow or reverse the progression of the disease. In an earlier release of data in the STRUT trial, AmpionTM demonstrated clinically significant cartilage growth of .02mm in as little as 3 months with one injection compared to MRK’s drug Sprifermin which had the same .02mm growth in healthier knees but took 2 years to get to that level.

Likelihood of Marketing Approval

With 1 pivotal trial completed and another phase 3 trial that exceeded the endpoints the BLA has met the prerequisite requirements defined by the FDA AMPE can look forward to the labeling of the drug and eventually approval. The company has indicated on the latest conference call that they have enough money to complete the BLA and expect to have it done by Q3 if not sooner. It was also included as part of their budgeted burn rate which means they are working on it now. There are some great statistics in the pharmaceutical industry that break down the Likelihood of Approval (LOA) and the next milestone for this company is submitting the BLA license. Assuming they have the BLA done and have submitted the file to the FDA, investors can anticipate the probability of approval is 88.4% according to the Biotech Innovation Organization. The market should start factoring this probability into the stock price as time progresses but might need a catalyst.

Valuation and Market Disconnect

At times the market can be very inefficient at price discovery which could lead to huge swoons and falls in price in the presence of a catalyst. In the case of AMPE, the market disconnect from true valuation is more pronounced so it’s important to look at what factors are impeding true price discovery.

The first factor is the markets fear of further dilution. The company did a couple of rounds of what was viewed as dilutive financing. The company stated on the last conference call that they had $11.2 million in cash, access to a credit facility, and over 5 million warrants in the money that have not yet been exercised. This translates into an $830,000 monthly burn rate with enough cash to take them through January 2019.

The next factor deals with AMPE’s ability to get a licensing deal. The market is simply impatient and feels that if the drug is as good as claimed it shouldn’t take so long to get a licensing deal. The absence of a licensing deal announcement has put considerable pressure on the stock. Adding to the pressure is very high level of short interest in the stock with 13.1% of the float short. The stock is number 18 on the largest short position list. There are also “Fake News” reports weighing heavily on the stock price suggesting that AmpionTM is no better than saline playing on investor’s fears that drug approval is not likely. This negative sentiment is weighing heavily on stock price and the catalyst that could break this deadlock is a licensing deal as it puts to rest the issue of dilution and the ability to generate meaningful revenue.

View the risk adjusted NPV worksheet here: http://emerginggrowth.com/wp-content/uploads/2018/03/AMPE-4.png

Net Present Value Model vs Appraisal

The net present value model risk adjusted is a summation of all the future earnings streams and discounted into today’s dollars. Valuations balloon in this model using even the most conservative numbers. Readers should notice the model uses a 9% probability of approval, which is typically the baseline for a New Drug Application (NDA). The profit per dose of $200 is based off the current retail price of Hyaluronic acid which ranges from $300 – $750 per injection. According to AMPE, the label will stipulate up to 5 injections per year which places the profit per patient at $1000 per year. The current risk adjusted model places a $9.533 billion valuation on AMPE using these assumption.

The probability of approval number should be 88.4% and if used in the model with ONLY KL-4 patients yields a risk adjusted value of $6.524 billion.

Although no valuation report was made public, methodology would be the same and include more indication as this model does but with one major caveat. In all likelihood the model DID NOT include 100% market share of the KL-4 patients because that data was just released and the company had indicated the valuation was completed and in the 10 digits.

This last trial data release was a major game changer in valuation because instead of having to build a sales force to achieve market penetration AMPE gets it on day 1 as this is likely to be a mandated first line therapy. Orthopedic surgeons should have no choice but to try it before they can do surgery.

The model is extremely conservative and allows investors to throw out the opiate abusers and other joint surgeries and still and get a valuation in the billions. CEO Macaluso said an appraisal was done with figures in the “ten digit area” and expects the new appraisal with the expanded label will be “multiples” of that. This means the company has gone on record with a $2 billion plus appraisal yet the market capitalization sits at $200 million roughly 10% of its potential value according to the Company.

View the complete article including the valuation gap and Investment summary with price target here: http://emerginggrowth.com/ampio-pharmaceuticals-inc-nasdaq-ampe-extended-trial-shows-patients-can-avoid-total-knee-replacement/

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. EmergingGrowth.com has not been compensated by, any company mentioned in this article. Please read our full disclosure, which can be found here, http://emerginggrowth.com/disclosure/. Please consult an investment professional before investing in anything viewed within this article or any other portion of EmergingGrowth.com. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Emerging Growth Staff
EmergingGrowth.com
305-330-1985
email us here


Source: EIN Presswire

Can You Afford In-Home Care? Here are Some Tips on How to Cut the Cost

Comfort Keepers Warren NJ

Comfort Keepers of Warren, NJ

Comfort Keepers of Warren NJ has a List of Shared Economy Tactics People Can Use to Afford In Home Care

People want the best for their loved ones when it comes to home care, but the scary question is always 'how can I afford it?'”

— Stephanie Howe

WARREN, NEW JERSEY, UNITED STATES, March 30, 2018 /EINPresswire.com/ — For most of us, the body starts to slow down sometime between 30 and 40 and it never really stops. Aging creates challenges for people, and while some remain vigorous and physically active well into their 80s and beyond, many retirees find themselves less active and less able to take care of strenuous or exhausting tasks. When this happens to your aging parents or grandparents, the natural solution is to hire in-home care, at least for a few hours a day to help keep up with chores and keep your loved company while you are distracted with things like your job or your own children.

But what if you didn't plan on budgeting for in-home care for your elder parents or grandparents? Most people are still struggling to save for their own retirement and haven't begun to consider the costs that come with assisting their older family members in a society that is aging rapidly.

The good news is that you don't have to rely on your spare time or that of your siblings if you're willing to get resourceful with modern opportunities.

Stephanie Howe, the owner of Comfort Keepers in Warren, NJ, is an expert on budgeting and paying for in-home care. Howe has been running a multi-location home caregiver business throughout Central New Jersey since 2005 and in those 13 years, she has seen a variety of innovative methods to help alleviate the costs of in-home care.

"We know that one of the biggest concerns anyone has when it comes to in-home care," says Howe, "is the cost. People want the best for their loved ones when it comes to home care, but the scary question is always 'how can I afford it?'"

Howe notes that costs tend to vary based on insurance and benefits and this creates a lot of trepidation among people who know they have relatives that need the care but don't know if they can fit it into their budget.

"Each insurance provider and each retirement plan can be different," she says. "But while that makes it a case-by-case conversation, and one we're always looking to help explore the options with, there are a lot of common tips we can share that anyone can do to help."

Comfort Keepers of Warren, NJ, has devised a tip sheet based the sharing economy. This tip sheet taps into things anyone, no matter what age, can do to offset the cost of in-home care through goods and services or trade.

"This isn't a substitute for benefits or insurance," Howe adds. "These are just common things that we have seen clients' families have had success with to add that extra little bit."

Howe notes that Comfort Keepers of Warren, NJ, has a staff of experts that can assist anyone curious about in-home care. This staff will explore options for payment finding the best overall plan. But, Howe adds, the tips list has proven successful in individual cases.

How to Use the Sharing Economy to Help Pay for In-Home Care

Comfort Keepers of Warren, NJ, suggests any of these activities may help:

1) Airbnb Your Spare Rooms

Many retirees looking to age in place have a home big enough for a busy family, but their adult children have moved away and bought homes of their own. This means that you may have plenty of spare rooms to host one large or several small Airbnb listings. If you haven't heard of Airbnb, it is almost exactly what it sounds like. People with spare bedrooms and homes make listings and rent out nights like hotel rooms. All you need to do is keep the rooms decorated and nice and stock a supply of hotel soaps. Maintenance is easy, and a relative might be willing to assist you in setting up and decorating the space to start with.

2) Rent Out Your Parking Space

If you live in an urban area where parking is tight but have an extra parking space available either on the street, in the driveway, or in your garage, you can rent it out through the sharing economy. With even fewer maintenance requirements than an Airbnb, nice people visiting relatives or traveling for work who need a guaranteed safe and legal place to park can book your spot for anywhere from an hour to a week. This is a great way to collect some additional income often without even needing to speak to your guests.

3) Pet Sitting for Your Kind of Pet

For seniors who already have a dog or a cat, many pet owners turn to the sharing economy to take care of their furry friends when they have to go on vacation or a business trip. Compared to kennelling services, sending your pet to 'camp' in another pet-friendly home allows them to make friends, roam, and play instead of spending all weekend in a crate. It's easy to believe that pet parents would be more than happy to pay for this service with the same budget they would have spent on kennelling.

Your Caregiver and the Sharing Economy

Once your sharing economy income starts to generate if you choose to hire an in-home caregiver, be sure to talk to them about also being a part of your sharing economy hobbies. You could re-decorate your Airbnb suite together, think of fun activities for visiting pets, or even start getting creative with the favor economy where neighbors swap favors for cash and bartering all the time from lawnmower trades to batches of homemade pies. Not only is the sharing economy a great way to pay for in-home care, but it's also a fantastic source of activity and socialization.

About Comfort Keepers of Warren, NJ

Comfort Keepers provides award-winning in-home care for seniors and other adults in need of assistance with daily activities. Their highly trained and dedicated caregivers can help your loved one stay in their home for as long as safely possible—a dream come true for both the seniors and their families. Their goal is to enrich the lives of every treasured client while maintaining client safety, well-being, and comfort as each person continues to live independently despite disease and other age-related conditions.

Their caregivers, referred to as Comfort Keepers®, are carefully selected, screened, and trained to provide professional, compassionate assistance that meets the organization’s high standards. Through a unique approach called Interactive Caregiving™, Comfort Keepers' caregivers build true friendships with their clients in order to fulfill their emotional and social needs.

To find out more about Comfort Keepers of Warren New Jersey’s commitment to excellence, please call (732) 369-3639.

This release was drafted by Results Driven Marketing, LLC: a full-service digital marketing, public relations, advertising and content marketing firm located in Philadelphia, PA

Joe Fuhrman
Comfort Keepers, Warren, NJ
(732) 369-3639
email us here


Source: EIN Presswire

Pharmacovigilance Software Market 2018-Global Industry Analysis, By Key Players, Segmentation, Trends & Forecast By 2023

Pharmacovigilance Software – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023

PUNE, MAHARASHTRA, INDIA, March 30, 2018 /EINPresswire.com/ — Pharmacovigilance Software Market 2018    

Description: 

The Pharmacovigilance Software market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.Based on the Pharmacovigilance Software industrial chain, this report mainly elaborate the definition, types, applications and major players of Pharmacovigilance Software market in details. Deep analysis about market status (2013-2018), enterprise competition pattern, advantages and disadvantages of enterprise Products, industry development trends (2018-2023), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Pharmacovigilance Software market.
The Pharmacovigilance Software market can be split based on product types, major applications, and important regions.

Major Players in Pharmacovigilance Software market are:
Sparta Systems, Inc 
United BioSource Corporation 
ArisGlobal 
Sarjen Systems Pvt. Ltd 
Online Business Applications, Inc 
EXTEDO GmbH 
Oracle Corporation 
Ennov Solutions Inc 

Request for Sample Report@ https://www.wiseguyreports.com/sample-request/3052921-global-pharmacovigilance-software-industry-market-research-report

Major Regions play vital role in Pharmacovigilance Software market are:
North America
Europe
China
Japan
Middle East & Africa
India
South America
Others

Most important types of Pharmacovigilance Software products covered in this report are:
Adverse Event Reporting
Fully Integrated Software

Most widely used downstream fields of Pharmacovigilance Software market covered in this report are:
Pharma & Biotech Companies
Contract research organizations (CROs)
Business process outsourcing firms (BPOs)

There are 13 Chapters to thoroughly display the Pharmacovigilance Software market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: Pharmacovigilance Software Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Pharmacovigilance Software Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Pharmacovigilance Software.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Pharmacovigilance Software.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Pharmacovigilance Software by Regions (2013-2018).

Chapter 6: Pharmacovigilance Software Production, Consumption, Export and Import by Regions (2013-2018).

Chapter 7: Pharmacovigilance Software Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Pharmacovigilance Software.

Chapter 9: Pharmacovigilance Software Market Analysis and Forecast by Type and Application (2018-2023).

Chapter 10: Market Analysis and Forecast by Regions (2018-2023).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

Complete report details @ https://www.wiseguyreports.com/reports/3052921-global-pharmacovigilance-software-industry-market-research-report

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

Global Pharmacovigilance Software Industry Market Research Report
1 Pharmacovigilance Software Introduction and Market Overview
1.1 Objectives of the Study
1.2 Definition of Pharmacovigilance Software
1.3 Pharmacovigilance Software Market Scope and Market Size Estimation
1.3.1 Market Concentration Ratio and Market Maturity Analysis
1.3.2 Global Pharmacovigilance Software Value ($) and Growth Rate from 2013-2023
1.4 Market Segmentation
1.4.1 Types of Pharmacovigilance Software
1.4.2 Applications of Pharmacovigilance Software
1.4.3 Research Regions
1.4.3.1 North America Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.2 Europe Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.3 China Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.4 Japan Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.5 Middle East & Africa Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.6 India Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.4.3.7 South America Pharmacovigilance Software Production Value ($) and Growth Rate (2013-2018)
1.5 Market Dynamics
1.5.1 Drivers
1.5.1.1 Emerging Countries of Pharmacovigilance Software
1.5.1.2 Growing Market of Pharmacovigilance Software
1.5.2 Limitations
1.5.3 Opportunities
1.6 Industry News and Policies by Regions
1.6.1 Industry News
1.6.2 Industry Policies

2 Industry Chain Analysis
2.1 Upstream Raw Material Suppliers of Pharmacovigilance Software Analysis
2.2 Major Players of Pharmacovigilance Software
2.2.1 Major Players Manufacturing Base and Market Share of Pharmacovigilance Software in 2017
2.2.2 Major Players Product Types in 2017
2.3 Pharmacovigilance Software Manufacturing Cost Structure Analysis
2.3.1 Production Process Analysis
2.3.2 Manufacturing Cost Structure of Pharmacovigilance Software
2.3.3 Raw Material Cost of Pharmacovigilance Software
2.3.4 Labor Cost of Pharmacovigilance Software
2.4 Market Channel Analysis of Pharmacovigilance Software
2.5 Major Downstream Buyers of Pharmacovigilance Software Analysis

…….

8 Competitive Landscape
8.1 Competitive Profile
8.2 Sparta Systems, Inc 
8.2.1 Company Profiles
8.2.2 Pharmacovigilance Software Product Introduction
8.2.3 Sparta Systems, Inc Production, Value ($), Price, Gross Margin 2013-2018E
8.2.4 Sparta Systems, Inc Market Share of Pharmacovigilance Software Segmented by Region in 2017
8.3 United BioSource Corporation 
8.3.1 Company Profiles
8.3.2 Pharmacovigilance Software Product Introduction
8.3.3 United BioSource Corporation Production, Value ($), Price, Gross Margin 2013-2018E
8.3.4 United BioSource Corporation Market Share of Pharmacovigilance Software Segmented by Region in 2017
8.4 ArisGlobal 
8.4.1 Company Profiles
8.4.2 Pharmacovigilance Software Product Introduction
8.4.3 ArisGlobal Production, Value ($), Price, Gross Margin 2013-2018E
8.4.4 ArisGlobal Market Share of Pharmacovigilance Software Segmented by Region in 2017
8.5 Sarjen Systems Pvt. Ltd 
8.5.1 Company Profiles
8.5.2 Pharmacovigilance Software Product Introduction
8.5.3 Sarjen Systems Pvt. Ltd Production, Value ($), Price, Gross Margin 2013-2018E
8.5.4 Sarjen Systems Pvt. Ltd Market Share of Pharmacovigilance Software Segmented by Region in 2017
8.6 Online Business Applications, Inc 
8.6.1 Company Profiles
8.6.2 Pharmacovigilance Software Product Introduction
8.6.3 Online Business Applications, Inc Production, Value ($), Price, Gross Margin 2013-2018E
8.6.4 Online Business Applications, Inc Market Share of Pharmacovigilance Software Segmented by Region in 2017
8.7 EXTEDO GmbH 
8.8 Oracle Corporation 
8.9 Ennov Solutions Inc 

Continued…..

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

IQ4I Research & Consultancy published a new report on “In-Vitro Diagnostics Global Market – Forecast To 2023”

IVD is used to check the state of health, to cure, mitigate, treat or prevent disease. Growing healthcare expenditure,lifestyle diseases are driving the market.

In-Vitro Diagnostics Global Market is estimated to be worth $78,408.6 million by 2023”

— IQ4I Analyst

BOSTON, MASSACHUSETTS, U.S., March 30, 2018 /EINPresswire.com/ — In-vitro diagnostics is an integral part of the healthcare system enabling diagnosis, monitoring, screening and assessing predisposition of various diseases there by providing timely and targeted medical treatment which further reduces hospital stays and overall healthcare cost leading to economic growth in a long run. In-vitro diagnostics tools have developed as more sophisticated, portable, easy to use next generation devices giving precise, reliable results in a wide range of applications which include infectious diseases, cancer, diabetes, urological disorders, cardiac markers, genetic diseases and pharmacogenomics, autoimmune diseases and drug of abuse testing.

In-vitro diagnostics technologies are differentiated into different types based on the basic phenomenon used for diagnosing; these include immunoassays, clinical chemistry, molecular diagnostics, clinical microbiology, haematology, coagulation & haemostasis, and other IVD technologies. According to IQ4I estimation, the in-vitro diagnostics global market is expected to reach $78,408.6 million by 2023 growing at a mid-single digit CAGR from 2016-2023. Rise in prevalence of infectious and chronic diseases, increasing adoption of point of care testing, emergence of next generation molecular diagnostics, and growing awareness of companion diagnostics and personalized medicine, emergence of minimally invasive and non invasive diagnostics and rising number of CLIA waived IVD tests are contributing to the stable growth of IVD market. However, rising incidence of product recalls in the past year, lack of skilled laboratory technicians in developing nations, inadequate reimbursements, and unorganized regulatory framework are causing the market to slow down.

The in-vitro diagnostics market is segmented into technology, applications, products, sample type, end users and by geography. Among the various technologies immunochemistry occupies major share in the global technology market and molecular diagnostics surpassed all the technologies with a mid single digit CAGR during the period of 2016-2023. Transplantation diagnostics has emerged as the fastest growing application growing with a double digit CAGR due to the advent of HLA specific assays, which could precisely detect the organ compatibility and provide useful results in minimal time. The infectious disease testing occupied the largest share in the global applications market due to the high rate of sexually transmitted diseases such as HIV, Chlamydia, Gonorrhoea, and Syphilis.

Blood test is the most commonly used sample type which gives very precise results and provides useful insights on the disease diagnosis. Among the various samples used in IVD testing, blood sample occupied the biggest share in the IVD global market and is the fastest growing sample type. Other sample types such as urine are collected by non-invasive methods and are used for specific tests which include some of the clinical chemistry tests and more popularly pregnancy tests. Saliva tests have been performed for testing HIV, hypogonadism, measles, hepatitis and oral cancers. The OraRiskHPV test by Oral DNA labs is a non-invasive, easy-to-use screening tool for identification of oral HPV, a mucosal viral infection that could potentially lead to oral cancer.

Among the different product types, reagents contributed to the largest share and are the fastest growing product segment due to high demand of assay kits and comparative lower sales of assay instruments due to their high life span.
In-vitro diagnostics find their end users in hospitals, laboratories, academics and research centres, home care and others. Hospital occupied a major share and is the largest segment in the end users global market and home care is predicted to be the fastest growing with a high single digit CAGR from 2016-2023.

The IVD market is dominated by four major players namely Hoffman La Roche, Abbott Laboratories, Siemens AG, and Danaher Corporation which occupy a significant share of the total market share. Further the companies are acquiring other significant players in the market to retain their leadership in the market. For instance, in November 2016, Danaher Corporation acquired Cepheid for approximately $4 billion transforming its molecular diagnostics portfolio and bringing a double digit growth for the already flourishing diagnostics business of Danaher.

Geographically, North America commanded the largest share in the in-vitro diagnostics global market 2016. Asia-Pacific is expected to grow at high single digit growth rate countries with emerging countries representing huge growth opportunities for the in-vitro diagnostics market to flourish.

Major players in the in-vitro diagnostics global market include Hoffmann La Roche (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Sysmex Corporation (Japan), Johnson and Johnson (U.S.), Carlyle group (Ortho clinical diagnostics, U.S.), Biomerieux (France), and ThermoFisher Scientific (U.S.)

Other key players in the in-vitro diagnostics market include Qiagen NV (Netherlands), Grifols (U.S.), Diasorin (Italy), Hologic Inc (U.S.), and Quest diagnostics (U.S.).

Mr. Satish Birudukota
IQ4I Research & Consultancy Pvt Ltd.,
+91-80-8147030229
email us here


Source: EIN Presswire

Breast Imaging Devices Market 2018 Global Industry Key Players, Share, Trend, Segmentation and Forecast to 2025

Breast Imaging Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025

PUNE, INDIA, March 30, 2018 /EINPresswire.com/ — Breast Imaging Devices Market 2018

Wiseguyreports.Com adds “Breast Imaging Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database.

Report Details:

This report provides in depth study of “Breast Imaging Devices Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Breast Imaging Devices Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Global Breast Imaging Devices market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer;

The Top key players including;
GE Healthcare 
Philips 
Toshiba 
Hologic 
Siemens 
Sonocine,Inc. 
Perlong Medical 
Anke 
Angell 
Dilon Technologies,Inc. 
Aurora 
Sinomdt 
Macroo 
Orich Medical Equipment 
Planmed 
Metaltronica 
Fujifilm 
IMS 
Genoray 

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3081230-global-breast-imaging-devices-market-research-report-2018

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Breast Imaging Devices in these regions, from 2013 to 2025 (forecast), covering 
North America 
Europe 
China 
Japan 
Southeast Asia 
India 

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
Ionized Breast Imaging Device 
Non Ionized Breast Imaging Device 

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including 
Hospitals 
Clinics 
Other

This report provides valuable information for companies like manufacturers, suppliers, distributors, traders, customers, investors and individuals who have interests in this industry.

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@ https://www.wiseguyreports.com/reports/3081230-global-breast-imaging-devices-market-research-report-2018

Major Key Points in Table of Content:

Global Breast Imaging Devices Market Research Report 2018 
1 Breast Imaging Devices Market Overview 
1.1 Product Overview and Scope of Breast Imaging Devices 
1.2 Breast Imaging Devices Segment by Type (Product Category) 
1.2.1 Global Breast Imaging Devices Production and CAGR (%) Comparison by Type (Product Category)(2013-2025) 
1.2.2 Global Breast Imaging Devices Production Market Share by Type (Product Category) in 2017 
1.2.3 Ionized Breast Imaging Device 
1.2.4 Non Ionized Breast Imaging Device 
1.3 Global Breast Imaging Devices Segment by Application 
1.3.1 Breast Imaging Devices Consumption (Sales) Comparison by Application (2013-2025) 
1.3.2 Hospitals 
1.3.3 Clinics 
1.3.4 Other 
1.4 Global Breast Imaging Devices Market by Region (2013-2025) 
1.4.1 Global Breast Imaging Devices Market Size (Value) and CAGR (%) Comparison by Region (2013-2025) 
1.4.2 North America Status and Prospect (2013-2025) 
1.4.3 Europe Status and Prospect (2013-2025) 
1.4.4 China Status and Prospect (2013-2025) 
1.4.5 Japan Status and Prospect (2013-2025) 
1.4.6 Southeast Asia Status and Prospect (2013-2025) 
1.4.7 India Status and Prospect (2013-2025) 
1.5 Global Market Size (Value) of Breast Imaging Devices (2013-2025) 
1.5.1 Global Breast Imaging Devices Revenue Status and Outlook (2013-2025) 
1.5.2 Global Breast Imaging Devices Capacity, Production Status and Outlook (2013-2025)

….

7 Global Breast Imaging Devices Manufacturers Profiles/Analysis 
7.1 GE Healthcare 
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.1.2 Breast Imaging Devices Product Category, Application and Specification 
7.1.2.1 Product A 
7.1.2.2 Product B 
7.1.3 GE Healthcare Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.1.4 Main Business/Business Overview 
7.2 Philips 
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.2.2 Breast Imaging Devices Product Category, Application and Specification 
7.2.2.1 Product A 
7.2.2.2 Product B 
7.2.3 Philips Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.2.4 Main Business/Business Overview 
7.3 Toshiba 
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.3.2 Breast Imaging Devices Product Category, Application and Specification 
7.3.2.1 Product A 
7.3.2.2 Product B 
7.3.3 Toshiba Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.3.4 Main Business/Business Overview 
7.4 Hologic 
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.4.2 Breast Imaging Devices Product Category, Application and Specification 
7.4.2.1 Product A 
7.4.2.2 Product B 
7.4.3 Hologic Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.4.4 Main Business/Business Overview 
7.5 Siemens 
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.5.2 Breast Imaging Devices Product Category, Application and Specification 
7.5.2.1 Product A 
7.5.2.2 Product B 
7.5.3 Siemens Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.5.4 Main Business/Business Overview 
7.6 Sonocine,Inc. 
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.6.2 Breast Imaging Devices Product Category, Application and Specification 
7.6.2.1 Product A 
7.6.2.2 Product B 
7.6.3 Sonocine,Inc. Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.6.4 Main Business/Business Overview 
7.7 Perlong Medical 
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.7.2 Breast Imaging Devices Product Category, Application and Specification 
7.7.2.1 Product A 
7.7.2.2 Product B 
7.7.3 Perlong Medical Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.7.4 Main Business/Business Overview 
7.8 Anke 
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.8.2 Breast Imaging Devices Product Category, Application and Specification 
7.8.2.1 Product A 
7.8.2.2 Product B 
7.8.3 Anke Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.8.4 Main Business/Business Overview 
7.9 Angell 
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.9.2 Breast Imaging Devices Product Category, Application and Specification 
7.9.2.1 Product A 
7.9.2.2 Product B 
7.9.3 Angell Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.9.4 Main Business/Business Overview 
7.10 Dilon Technologies,Inc. 
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.10.2 Breast Imaging Devices Product Category, Application and Specification 
7.10.2.1 Product A 
7.10.2.2 Product B 
7.10.3 Dilon Technologies,Inc. Breast Imaging Devices Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.10.4 Main Business/Business Overview 

Continued….

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Stem Cell Therapy Market Analysis, Growth, Global Trends, Opportunity & Forecast 2018 to 2022

Wise.Guy12

Wise.Guy.

PUNE, INDIA, March 30, 2018 /EINPresswire.com/ — WiseGuyRerports.com Presents “Global Stem Cell Therapy Market Report 2018” New Document to its Studies Database

With the slowdown in world economic growth, the Stem Cell Therapy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Stem Cell Therapy market size to maintain the average annual growth rate of 34.19% from 53 million $ in 2014 to 129 million $ in 2017, BisReport analysts believe that in the next few years, Stem Cell Therapy market size will be further expanded, we expect that by 2022, The market size of the Stem Cell Therapy will reach 390 million $.

 
This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data. 

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Free——Definition

Section (2 3): 1200 USD——Manufacturer Detail 
Cellular Dynamics International 
Osiris Therapeutics 
Vcanbio 
Gamida Cell 
Golden Meditech 
Celgene 
Guanhao Biotech 
Mesoblast 
Vericel Corporation 
Stemcell Technologes 
Beike Biotechnology 
Cytori Therapeutics 
Bioheart 
Athersys 
Geron 
Pluristem Therapeutics 
Fibrocell Science 
Ocata Therapeutics

 Request For Sample Report @ https://www.wiseguyreports.com/sample-request/3084615-global-stem-cell-therapy-market-report-2018                                                               

Section 4: 900 USD——Region Segmentation 
North America Country (United States, Canada) 
South America 
Asia Country (China, Japan, India, Korea) 
Europe Country (Germany, UK, France, Italy) 
Other Country (Middle East, Africa, GCC)

Section (5 6 7): 500 USD—— 
Product Type Segmentation (Autologous, Allogeneic) 
Industry Segmentation (CNS, CVS, GIT, Wounds and Injuries, Musculoskeletal) 
Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USD——Trend (2018-2022)

Section 9: 300 USD——Product Type Detail

Section 10: 700 USD——Downstream Consumer

Section 11: 200 USD——Cost Structure

Section 12: 500 USD——Conclusion

 

Table Of Contents:                                                                                                                          

Section 1 Stem Cell Therapy Product Definition

Section 2 Global Stem Cell Therapy Market Manufacturer Share and Market Overview 
    2.1 Global Manufacturer Stem Cell Therapy Shipments 
    2.2 Global Manufacturer Stem Cell Therapy Business Revenue 
    2.3 Global Stem Cell Therapy Market Overview

Section 3 Manufacturer Stem Cell Therapy Business Introduction 
    3.1 Cellular Dynamics International Stem Cell Therapy Business Introduction 
      3.1.1 Cellular Dynamics International Stem Cell Therapy Shipments, Price, Revenue and Gross profit 2014-2017 
      3.1.2 Cellular Dynamics International Stem Cell Therapy Business Distribution by Region 
      3.1.3 Cellular Dynamics International Interview Record 
      3.1.4 Cellular Dynamics International Stem Cell Therapy Business Profile 
      3.1.5 Cellular Dynamics International Stem Cell Therapy Product Specification

    3.2 Osiris Therapeutics Stem Cell Therapy Business Introduction 
      3.2.1 Osiris Therapeutics Stem Cell Therapy Shipments, Price, Revenue and Gross profit 2014-2017 
      3.2.2 Osiris Therapeutics Stem Cell Therapy Business Distribution by Region 
      3.2.3 Interview Record 
      3.2.4 Osiris Therapeutics Stem Cell Therapy Business Overview 
      3.2.5 Osiris Therapeutics Stem Cell Therapy Product Specification

    3.3 Vcanbio Stem Cell Therapy Business Introduction 
      3.3.1 Vcanbio Stem Cell Therapy Shipments, Price, Revenue and Gross profit 2014-2017 
      3.3.2 Vcanbio Stem Cell Therapy Business Distribution by Region 
      3.3.3 Interview Record 
      3.3.4 Vcanbio Stem Cell Therapy Business Overview 
      3.3.5 Vcanbio Stem Cell Therapy Product Specification

    3.4 Gamida Cell Stem Cell Therapy Business Introduction 
    3.5 Golden Meditech Stem Cell Therapy Business Introduction 
    3.6 Celgene Stem Cell Therapy Business Introduction 

Section 4 Global Stem Cell Therapy Market Segmentation (Region Level) 
    4.1 North America Country 
      4.1.1 United States Stem Cell Therapy Market Size and Price Analysis 2014-2017 
      4.1.2 Canada Stem Cell Therapy Market Size and Price Analysis 2014-2017 
    4.2 South America Country 
      4.2.1 South America Stem Cell Therapy Market Size and Price Analysis 2014-2017 
    4.3 Asia Country 
      4.3.1 China Stem Cell Therapy Market Size and Price Analysis 2014-2017 
      4.3.2 Japan Stem Cell Therapy Market Size and Price Analysis 2014-2017 
      4.3.3 India Stem Cell Therapy Market Size and Price Analysis 2014-2017 
      4.3.4 Korea Stem Cell Therapy Market Size and Price Analysis 2014-2017 

 Continued…….

Complete Report Details @ https://www.wiseguyreports.com/reports/3084615-global-stem-cell-therapy-market-report-2018                                                                          

 

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Nasal Delivery Market 2018- Global Industry Analysis, By Key Players, Segmentation, Trends And Forecast By 2025

Nasal Delivery – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025

PUNE, MAHARASHTRA, INDIA, March 30, 2018 /EINPresswire.com/ — Nasal Delivery Market 2018

Wiseguyreports.Com Adds “Nasal Delivery – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025” To Its Research Database.

Description: 

This report studies the global Nasal Delivery market, analyzes and researches the Nasal Delivery development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like 
Merck & Co., Inc. 
Novartis AG 
Glaxosmithkline PLC 
Johnson & Johnson Services, Inc. 
Pfizer Inc. 
3M 
Becton, Dickinson and Company 
Aegis Therapeutics LLC 
Aptargroup, Inc. 
Astrazeneca

Request for Sample Report@ https://www.wiseguyreports.com/sample-request/3092515-global-nasal-delivery-market-size-status-and-forecast-2025

Market segment by Regions/Countries, this report covers 
United States 
EU 
Japan 
China 
India 
Southeast Asia

Market segment by Type, the product can be split into 
Sprays 
Drops & Liquids 
Powders 
Gels

Market segment by Application, Nasal Delivery can be split into 
Allergic And Non-allergic Rhinitis 
Nose Congestion 
Vaccination 
Other Therapeutic Applications

Complete report details @ https://www.wiseguyreports.com/reports/3092515-global-nasal-delivery-market-size-status-and-forecast-2025

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

Global Nasal Delivery Market Size, Status and Forecast 2025 
1 Industry Overview of Nasal Delivery 
1.1 Nasal Delivery Market Overview 
1.1.1 Nasal Delivery Product Scope 
1.1.2 Market Status and Outlook 
1.2 Global Nasal Delivery Market Size and Analysis by Regions (2013-2018) 
1.2.1 United States 
1.2.2 EU 
1.2.3 Japan 
1.2.4 China 
1.2.5 India 
1.2.6 Southeast Asia 
1.3 Nasal Delivery Market by Type 
1.3.1 Sprays 
1.3.2 Drops & Liquids 
1.3.3 Powders 
1.3.4 Gels 
1.4 Nasal Delivery Market by End Users/Application 
1.4.1 Allergic And Non-allergic Rhinitis 
1.4.2 Nose Congestion 
1.4.3 Vaccination 
1.4.4 Other Therapeutic Applications

2 Global Nasal Delivery Competition Analysis by Players 
2.1 Nasal Delivery Market Size (Value) by Players (2013-2018) 
2.2 Competitive Status and Trend 
2.2.1 Market Concentration Rate 
2.2.2 Product/Service Differences 
2.2.3 New Entrants 
2.2.4 The Technology Trends in Future

…….

3 Company (Top Players) Profiles 
3.1 Merck & Co., Inc. 
3.1.1 Company Profile 
3.1.2 Main Business/Business Overview 
3.1.3 Products, Services and Solutions 
3.1.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.1.5 Recent Developments 
3.2 Novartis AG 
3.2.1 Company Profile 
3.2.2 Main Business/Business Overview 
3.2.3 Products, Services and Solutions 
3.2.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.2.5 Recent Developments 
3.3 Glaxosmithkline PLC 
3.3.1 Company Profile 
3.3.2 Main Business/Business Overview 
3.3.3 Products, Services and Solutions 
3.3.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.3.5 Recent Developments 
3.4 Johnson & Johnson Services, Inc. 
3.4.1 Company Profile 
3.4.2 Main Business/Business Overview 
3.4.3 Products, Services and Solutions 
3.4.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.4.5 Recent Developments 
3.5 Pfizer Inc. 
3.5.1 Company Profile 
3.5.2 Main Business/Business Overview 
3.5.3 Products, Services and Solutions 
3.5.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.5.5 Recent Developments 
3.6 3M 
3.6.1 Company Profile 
3.6.2 Main Business/Business Overview 
3.6.3 Products, Services and Solutions 
3.6.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.6.5 Recent Developments 
3.7 Becton, Dickinson and Company 
3.7.1 Company Profile 
3.7.2 Main Business/Business Overview 
3.7.3 Products, Services and Solutions 
3.7.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.7.5 Recent Developments 
3.8 Aegis Therapeutics LLC 
3.8.1 Company Profile 
3.8.2 Main Business/Business Overview 
3.8.3 Products, Services and Solutions 
3.8.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.8.5 Recent Developments 
3.9 Aptargroup, Inc. 
3.9.1 Company Profile 
3.9.2 Main Business/Business Overview 
3.9.3 Products, Services and Solutions 
3.9.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.9.5 Recent Developments 
3.10 Astrazeneca 
3.10.1 Company Profile 
3.10.2 Main Business/Business Overview 
3.10.3 Products, Services and Solutions 
3.10.4 Nasal Delivery Revenue (Million USD) (2013-2018) 
3.10.5 Recent Developments

Continued…..

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Ethylene Propylene Diene Rubber (EPDM) Market 2018 Global Share, Trend, Segmentation and Forecast to 2025

PUNE, INDIA, March 30, 2018 /EINPresswire.com/ —

Global Ethylene Propylene Diene Rubber (EPDM) Market

WiseGuyRerports.com Presents “Global Ethylene Propylene Diene Rubber (EPDM) Market Research Report 2018” New Document to its Studies Database. The Report Contain 118 Pages With Detailed Analysis.

Description

Global Ethylene Propylene Diene Rubber (EPDM) market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including 

Versalis (Polimeri Europa) 
Petrochina 
Exxonmobil Chemical 
SK Global Chemical 
Mitsui Chemicals 
Carlisle Companies 
DOW Elastomers 
John Manville 
JSR Corporation 
Kumho Polychem 
Lanxess 
Lion Copolymer 
OAO Nizhnekamskneftekhim 
Sumitomo Chemica 

 

Get sample Report @ https://www.wiseguyreports.com/sample-request/3092480-global-ethylene-propylene-diene-rubber-epdm-market-research-report-2018

 

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ethylene Propylene Diene Rubber (EPDM) in these regions, from 2013 to 2025 (forecast), covering 
North America 
Europe 
China 
Japan 
Southeast Asia 
India 

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
Ziegler-Natta Catalyst Technology 
Metallocene Catalyst Technology 
Ace Technology 

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including 
Automotive 
Building & Construction 
Tires and Tubes 
Wires & Cables 
Lubricant Additives

 

Complete Report Details @ https://www.wiseguyreports.com/reports/3092480-global-ethylene-propylene-diene-rubber-epdm-market-research-report-2018

 

Table of Contents -Major Key Points

Global Ethylene Propylene Diene Rubber (EPDM) Market Research Report 2018 
1 Ethylene Propylene Diene Rubber (EPDM) Market Overview 
1.1 Product Overview and Scope of Ethylene Propylene Diene Rubber (EPDM) 
1.2 Ethylene Propylene Diene Rubber (EPDM) Segment by Type (Product Category) 
1.2.1 Global Ethylene Propylene Diene Rubber (EPDM) Production and CAGR (%) Comparison by Type (Product Category)(2013-2025) 
1.2.2 Global Ethylene Propylene Diene Rubber (EPDM) Production Market Share by Type (Product Category) in 2017 
1.2.3 Ziegler-Natta Catalyst Technology 
1.2.4 Metallocene Catalyst Technology 
1.2.5 Ace Technology 
1.3 Global Ethylene Propylene Diene Rubber (EPDM) Segment by Application 
1.3.1 Ethylene Propylene Diene Rubber (EPDM) Consumption (Sales) Comparison by Application (2013-2025) 
1.3.2 Automotive 
1.3.3 Building & Construction 
1.3.4 Tires and Tubes 
1.3.5 Wires & Cables 
1.3.6 Lubricant Additives 
1.4 Global Ethylene Propylene Diene Rubber (EPDM) Market by Region (2013-2025) 
1.4.1 Global Ethylene Propylene Diene Rubber (EPDM) Market Size (Value) and CAGR (%) Comparison by Region (2013-2025) 
1.4.2 North America Status and Prospect (2013-2025) 
1.4.3 Europe Status and Prospect (2013-2025) 
1.4.4 China Status and Prospect (2013-2025) 
1.4.5 Japan Status and Prospect (2013-2025) 
1.4.6 Southeast Asia Status and Prospect (2013-2025) 
1.4.7 India Status and Prospect (2013-2025) 
1.5 Global Market Size (Value) of Ethylene Propylene Diene Rubber (EPDM) (2013-2025) 
1.5.1 Global Ethylene Propylene Diene Rubber (EPDM) Revenue Status and Outlook (2013-2025) 
1.5.2 Global Ethylene Propylene Diene Rubber (EPDM) Capacity, Production Status and Outlook (2013-2025)

……………

7 Global Ethylene Propylene Diene Rubber (EPDM) Manufacturers Profiles/Analysis 
7.1 Versalis (Polimeri Europa) 
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.1.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.1.2.1 Product A 
7.1.2.2 Product B 
7.1.3 Versalis (Polimeri Europa) Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.1.4 Main Business/Business Overview 
7.2 Petrochina 
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.2.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.2.2.1 Product A 
7.2.2.2 Product B 
7.2.3 Petrochina Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.2.4 Main Business/Business Overview 
7.3 Exxonmobil Chemical 
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.3.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.3.2.1 Product A 
7.3.2.2 Product B 
7.3.3 Exxonmobil Chemical Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.3.4 Main Business/Business Overview 
7.4 SK Global Chemical 
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.4.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.4.2.1 Product A 
7.4.2.2 Product B 
7.4.3 SK Global Chemical Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.4.4 Main Business/Business Overview 
7.5 Mitsui Chemicals 
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.5.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.5.2.1 Product A 
7.5.2.2 Product B 
7.5.3 Mitsui Chemicals Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.5.4 Main Business/Business Overview 
7.6 Carlisle Companies 
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.6.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.6.2.1 Product A 
7.6.2.2 Product B 
7.6.3 Carlisle Companies Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.6.4 Main Business/Business Overview 
7.7 DOW Elastomers 
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.7.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.7.2.1 Product A 
7.7.2.2 Product B 
7.7.3 DOW Elastomers Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.7.4 Main Business/Business Overview 
7.8 John Manville 
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.8.2 Ethylene Propylene Diene Rubber (EPDM) Product Category, Application and Specification 
7.8.2.1 Product A 
7.8.2.2 Product B 
7.8.3 John Manville Ethylene Propylene Diene Rubber (EPDM) Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 

………..CONTINUED

 

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire